So Yeon Kim, MD
Assistant ProfessorCards
About
Research
Publications
2025
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry
Cortellini A, Santo V, Brunetti L, Garbo E, Pinato D, La Cava G, Naidoo J, Katz A, Loza M, Neal J, Genova C, Gettinger S, Kim S, Jayakrishnan R, Zarif T, Russano M, Pecci F, Di Federico A, Alessi J, Montrone M, Owen D, Ramella S, Signorelli D, Fidler M, Li M, Camerini A, Halmos B, Vincenzi B, Metro G, Passiglia F, Yendamuri S, Guida A, Ghidini M, D’Alessio A, Banna G, Fulgenzi C, Grisanti S, Grossi F, D’Incecco A, Josephides E, Van Hemelrijck M, Russo A, Gelibter A, Spinelli G, Verrico M, Tomasik B, Giusti R, Balachandran K, Bria E, Sebastian M, Rost M, Forster M, Mukherjee U, Landi L, Mazzoni F, Aujayeb A, Dupont M, Curioni-Fontecedro A, Chiari R, Sforza V, Tiseo M, Friedlaender A, Addeo A, Zoratto F, De Tursi M, Cantini L, Roca E, Mountzios G, Rocco D, Della Gravara L, Kalvapudi S, Inno A, Bironzo P, Di Marco Barros R, O’Reilly D, Fitzpatrick O, Karapanagiotou E, Monnet I, Baena J, Macerelli M, Piedra A, Agustoni F, Cortinovis D, Tonini G, Minuti G, Bennati C, Mezquita L, Gorría T, Servetto A, Beninato T, Russo G, Prelaj A, De Giglio A, Rogado J, Moliner L, Nadal E, Biello F, Nana F, Dingemans A, Aerts J, Ferrara R, Abu Hejleh T, Takada K, Naqash A, Garassino M, Peters S, Wakelee H, Nassar A, Ricciuti B, Soda P, Caruso C, Guarrasi V. Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry. Journal For ImmunoTherapy Of Cancer 2025, 13: e012423. PMID: 41022528, PMCID: PMC12481261, DOI: 10.1136/jitc-2025-012423.Peer-Reviewed Original ResearchLasering in on Uncommon EGFR Mutations
Kim S, Politi K, Goldberg S. Lasering in on Uncommon EGFR Mutations. Journal Of Thoracic Oncology 2025, 20: 1148-1151. PMID: 40914593, DOI: 10.1016/j.jtho.2025.06.014.Peer-Reviewed Original ResearchSmall Cell Lung Cancer
Kim S, Park H, Chiang A. Small Cell Lung Cancer. JAMA 2025, 333: 1906-1917. PMID: 40163214, DOI: 10.1001/jama.2025.0560.Peer-Reviewed Original ResearchThis study investigates the treatment advancements for small cell lung cancer, showing that combining chemotherapy, radiotherapy, and immunotherapy improves survival rates, highlighting the importance of early diagnosis and tailored therapy.Comparative efficacy of immunotherapy-based treatment versus chemotherapy-only in patients with unresectable NSCLC with disease progression post chemoradiation and durvalumab
Cortiula F, Kutiel T, Hsu M, Hendriks L, Nassar A, Moskovitz M, Kim S, Mirsky M, Jayakrishnan R, Bortolot M, Saddi J, Borghetti P, Chung M, Filippi A, De Ruysscher D, Bar J. Comparative efficacy of immunotherapy-based treatment versus chemotherapy-only in patients with unresectable NSCLC with disease progression post chemoradiation and durvalumab. European Journal Of Cancer 2025, 219: 115302. PMID: 39987799, DOI: 10.1016/j.ejca.2025.115302.Peer-Reviewed Original ResearchAdultAgedAged, 80 and overAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungChemoradiotherapyDisease ProgressionFemaleHumansImmune Checkpoint InhibitorsImmunotherapyLung NeoplasmsMaleMiddle AgedRetrospective StudiesTreatment OutcomeDeterminants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry
Cortellini A, Brunetti L, Di Fazio G, Garbo E, Pinato D, Naidoo J, Katz A, Loza M, Neal J, Genova C, Gettinger S, Kim S, Jayakrishnan R, Zarif T, Russano M, Pecci F, Di Federico A, Awad M, Alessi J, Montrone M, Owen D, Signorelli D, Fidler M, Li M, Camerini A, De Giglio A, Young L, Vincenzi B, Metro G, Passiglia F, Yendamuri S, Guida A, Ghidini M, Awosika N, Napolitano A, Fulgenzi C, Grisanti S, Grossi F, D’Incecco A, Josephides E, Van Hemelrijck M, Russo A, Gelibter A, Spinelli G, Verrico M, Tomasik B, Giusti R, Newsom-Davis T, Bria E, Sebastian M, Rost M, Forster M, Mukherjee U, Landi L, Mazzoni F, Aujayeb A, Dupont M, Curioni-Fontecedro A, Chiari R, Pantano F, Morabito A, Leonetti A, Friedlaender A, Addeo A, Zoratto F, De Tursi M, Cantini L, Roca E, Mountzios G, Della Gravara L, Kalvapudi S, Inno A, Bironzo P, Di Marco Barros R, O’Reilly D, Bell J, Karapanagiotou E, Monnet I, Baena J, Macerelli M, Majem M, Agustoni F, Cortinovis D, Tonini G, Minuti G, Bennati C, Mezquita L, Gorría T, Servetto A, Beninato T, Russo G, Rogado J, Moliner L, Biello F, Nana F, Dingemans A, Aerts J, Ferrara R, Torri V, Abu Hejleh T, Takada K, Naqash A, Garassino M, Peters S, Wakelee H, Nassar A, Ricciuti B. Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry. Journal For ImmunoTherapy Of Cancer 2025, 13: e010674. PMID: 39904562, PMCID: PMC11795382, DOI: 10.1136/jitc-2024-010674.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerAdvanced non-small cell lung cancerProgrammed cell death ligand 1Eastern Cooperative Oncology Group performance statusData cut-offLong-term efficacyIndividual patient-level dataMedian OSPembrolizumab monotherapySurvival rateProgressive diseaseDiscontinued treatment due to progressive diseaseTreated with first-line pembrolizumabClinical trialsPredictors of 5-year survivalFirst-line pembrolizumab monotherapyCell death ligand 1Pre-existing autoimmune diseaseFirst-line pembrolizumabKEYNOTE-024 trialPD-L1 TPSPermanently discontinue treatmentDeath-ligand 1Efficacy of pembrolizumabMedian Follow-Up
2024
P3.06E.01 Evaluation of the Immune Landscape of Patients with Adenosquamous NSCLC (LUAS)
Lee M, Adeyelu T, Wang S, Elliott A, Vanderwalde A, Villaruz L, Khan H, Herzberg B, Kim S, Ma P, Liu S, Halmos B, Cheng H. P3.06E.01 Evaluation of the Immune Landscape of Patients with Adenosquamous NSCLC (LUAS). Journal Of Thoracic Oncology 2024, 19: s328-s329. DOI: 10.1016/j.jtho.2024.09.590.Peer-Reviewed Original ResearchEvaluation of the genomic and immune profiles of patients with lung adenosquamous carcinoma (LUAS) and association of response to treatment.
Lee M, Adeyelu T, Wang S, Elliott A, Vanderwalde A, Villaruz L, Khan H, Herzberg B, Kim S, Ma P, Liu S, Halmos B, Cheng H. Evaluation of the genomic and immune profiles of patients with lung adenosquamous carcinoma (LUAS) and association of response to treatment. Journal Of Clinical Oncology 2024, 42: 8567-8567. DOI: 10.1200/jco.2024.42.16_suppl.8567.Peer-Reviewed Original ResearchClinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes
Nassar A, El Zarif T, Khalid A, Rahme S, Zhong C, Kwak L, Salame M, Farhat E, Freeman D, El-Am E, Ravishankar A, Ahmad B, Nana F, Kaldas D, Naqash A, Sharon E, LeBoeuf N, Cortellini A, Malgeri A, Gupta S, Al-Hader A, Sparks J, Linnoila J, Hamnvik O, Mouhieddine T, Marron T, Parikh K, McKay R, Dilling T, Choueiri T, Adib E, Najem E, Kim S, Sonpavde G. Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes. Journal For ImmunoTherapy Of Cancer 2024, 12: e008724. PMID: 38448038, PMCID: PMC10916116, DOI: 10.1136/jitc-2023-008724.Peer-Reviewed Original Research
2023
P1.12-08 Characterization of MET Exon 14 Skipping Analog (Y1003) in Non-Small Cell Lung Cancer (NSCLC)
Kim S, Narvel H, Gandhi N, Marks J, Zaemes J, Dacic S, Liu S, Kim C, Ma P, Reckamp K, Feldman R, Nagasaka M, Khan H, Uprety D, Xiu J, Vanderwalde A, Cheng H, Halmos B. P1.12-08 Characterization of MET Exon 14 Skipping Analog (Y1003) in Non-Small Cell Lung Cancer (NSCLC). Journal Of Thoracic Oncology 2023, 18: s210-s211. DOI: 10.1016/j.jtho.2023.09.337.Peer-Reviewed Original ResearchCo-mutational status and PD-L1 expression in KRAS mutant non-small cell lung cancer (NSCLC): Role in treatment selection and association with clinical outcomes.
Khan H, Judd J, Xiu J, Ullah A, Raval G, Ma P, Nieva J, Radovich M, Oberley M, Kim S, Mamdani H, Raez L, Vanderwalde A, Halmos B, Borghaei H, Liu S, Abdel Karim N. Co-mutational status and PD-L1 expression in KRAS mutant non-small cell lung cancer (NSCLC): Role in treatment selection and association with clinical outcomes. Journal Of Clinical Oncology 2023, 41: 9038-9038. DOI: 10.1200/jco.2023.41.16_suppl.9038.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
Clinical Care
Overview
So Yeon Kim, MD, is a medical oncologist who cares for patients with lung cancer, an area that she says is changing rapidly, thanks to new drugs in the past decade, targeted treatments, and immunotherapies that have led to significant improvements in outcomes even in people with advanced forms of the disease.
“I always knew I wanted to do something to help people,” Dr. Kim says. “I ultimately chose oncology because I enjoyed the long-term relationships I was able to build with patients and families. I really enjoy working with cancer patients because they are among the most resilient and courageous people, who continue to fight against a disease that still has many more problems to solve.”
Dr. Kim is working with colleagues toward personalizing cancer treatment for all patients with carefully selected treatment options based on the tumor’s “molecular fingerprint,” she says. “At Yale, there is a lot of ongoing scientific collaboration between clinicians and researchers that is helping bring the latest scientific discoveries to patients with the goal of improving their outcomes.”
An assistant professor at Yale School of Medicine, Dr. Kim focuses her research on both targeted treatment options and immunotherapy. “Oncology is a humbling field that can bring up more questions than answers, but I think that ultimately allows space for creativity and innovation,” she says. “While my research interests currently remain broad, I am interested in developing a more personalized approach to lung cancer care as we learn more about the science around what drives specific patients to respond better to certain therapies than to others,” she says.
Clinical Specialties
Fact Sheets
Lung Cancer
Learn More on Yale MedicineLung Cancer in Nonsmokers
Learn More on Yale MedicineRadiofrequency Ablation (RFA)
Learn More on Yale MedicineNon-Small Cell Lung Cancer
Learn More on Yale Medicine
Board Certifications
Medical Oncology
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2022
Hematology (Internal Medicine)
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2021
Internal Medicine
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2019
Yale Medicine News
News
News
- July 07, 2025
International Exchange Fosters Clinical and Research Collaboration
- June 06, 2025
Yale Cancer Center Researchers and Trainees Present at 2025 ASCO Annual Meeting
- November 14, 2024
Understanding Lung Cancer: A Conference to Raise Awareness and Offer Hope to Those Impacted by Lung Cancer
- January 31, 2024
Why a Targeted Therapy Is Better Than Immunotherapy for Some Patients With Inoperable Non-Small Cell Lung Cancer
Get In Touch
Contacts
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.